Suzette A Priola

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7325769/publications.pdf

Version: 2024-02-01

57 papers	4,049 citations	172457 29 h-index	168389 53 g-index
57 all docs	57 docs citations	57 times ranked	2365 citing authors

#	Article	IF	Citations
1	Cell-free formation of protease-resistant prion protein. Nature, 1994, 370, 471-474.	27.8	859
2	Anchorless Prion Protein Results in Infectious Amyloid Disease Without Clinical Scrapie. Science, 2005, 308, 1435-1439.	12.6	585
3	Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nature Methods, 2007, 4, 645-650.	19.0	305
4	Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature, 1997, 388, 285-288.	27.8	259
5	Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron, 1995, 15, 1183-1191.	8.1	149
6	Susceptibilities of Nonhuman Primates to Chronic Wasting Disease. Emerging Infectious Diseases, 2009, 15, 1366-1376.	4.3	133
7	Multiple Amino Acid Residues within the Rabbit Prion Protein Inhibit Formation of Its Abnormal Isoform. Journal of Virology, 2003, 77, 2003-2009.	3.4	117
8	Susceptibility of Common Fibroblast Cell Lines to Transmissible Spongiform Encephalopathy Agents. Journal of Infectious Diseases, 2004, 189, 431-439.	4.0	115
9	DNA Aptamers That Bind to PrP^C and Not Prp^{Sc} Show Sequence and Structure Specificity. Experimental Biology and Medicine, 2006, 231, 204-214.	2.4	89
10	A 60-kDa Prion Protein (PrP) with Properties of Both the Normal and Scrapie-associated Forms of PrP. Journal of Biological Chemistry, 1995, 270, 3299-3305.	3.4	82
11	Abnormal Properties of Prion Protein with Insertional Mutations in Different Cell Types. Journal of Biological Chemistry, 1998, 273, 11980-11985.	3.4	81
12	N-terminal Truncation of Prion Protein Affects Both Formation and Conformation of Abnormal Protease-resistant Prion Protein Generatedin Vitro. Journal of Biological Chemistry, 2001, 276, 35265-35271.	3.4	80
13	Prion protein misfolding and disease. Current Opinion in Structural Biology, 2009, 19, 14-22.	5.7	73
14	Molecular Basis of Scrapie Strain Glycoform Variation. Journal of Biological Chemistry, 2002, 277, 36775-36781.	3.4	68
15	Efficient Conversion of Normal Prion Protein (PrP) by Abnormal Hamster PrP Is Determined by Homology at Amino Acid Residue 155. Journal of Virology, 2001, 75, 4673-4680.	3.4	66
16	Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation. Protein Science, 2006, 15, 609-619.	7.6	61
17	Inhibition of scrapie-associated PrP accumulation. Molecular Neurobiology, 1994, 8, 113-120.	4.0	58
18	Flexible N-terminal Region of Prion Protein Influences Conformation of Protease-resistant Prion Protein Isoforms Associated with Cross-species Scrapie Infection in Vivo and in Vitro. Journal of Biological Chemistry, 2004, 279, 13689-13695.	3.4	58

#	Article	IF	Citations
19	Cells Expressing Anchorless Prion Protein Are Resistant to Scrapie Infection. Journal of Virology, 2009, 83, 4469-4475.	3.4	57
20	Acute Formation of Protease-resistant Prion Protein Does Not Always Lead to Persistent Scrapie Infection in Vitro. Journal of Biological Chemistry, 2004, 279, 29218-29225.	3.4	56
21	Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity. Journal of Neuroscience, 2007, 27, 9537-9544.	3.6	56
22	Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent. Virology, 2008, 379, 284-293.	2.4	44
23	Recombinant Prion Protein Refolded with Lipid and RNA Has the Biochemical Hallmarks of a Prion but Lacks In Vivo Infectivity. PLoS ONE, 2013, 8, e71081.	2.5	40
24	Deletion of Î²-Strand and Î±-Helix Secondary Structure in Normal Prion Protein Inhibits Formation of Its Protease-Resistant Isoform. Journal of Virology, 2001, 75, 10024-10032.	3.4	36
25	Prophylactic and Therapeutic Effects of Phthalocyanine Tetrasulfonate in Scrapieâ€Infected Mice. Journal of Infectious Diseases, 2003, 188, 699-705.	4.0	36
26	Cyclic Tetrapyrrole Sulfonation, Metals, and Oligomerization in Antiprion Activity. Antimicrobial Agents and Chemotherapy, 2007, 51, 3887-3894.	3.2	34
27	Amyloid Formation via Supramolecular Peptide Assemblies. Biochemistry, 2007, 46, 7079-7087.	2.5	33
28	The role of the prion protein membrane anchor in prion infection. Prion, 2009, 3, 134-138.	1.8	33
29	Cellular prion protein is present in mitochondria of healthy mice. Scientific Reports, 2017, 7, 41556.	3.3	32
30	BIOMEDICINE: A View from the Top--Prion Diseases from 10,000 Feet. Science, 2003, 300, 917-919.	12.6	31
31	Comparative profiling of highly enriched 22L and Chandler mouse scrapie prion protein preparations. Proteomics, 2010, 10, 2858-2869.	2.2	31
32	Prion strains depend on different endocytic routes for productive infection. Scientific Reports, 2017, 7, 6923.	3.3	29
33	Uptake and Degradation of Protease-Sensitive and -Resistant Forms of Abnormal Human Prion Protein Aggregates by Human Astrocytes. American Journal of Pathology, 2014, 184, 3299-3307.	3.8	28
34	Methods for Studying Prion Protein (PrP) Metabolism and the Formation of Protease-Resistant PrP in Cell Culture and Cell-Free Systems: An Update. Molecular Biotechnology, 1999, 13, 45-56.	2.4	27
35	Mitochondrial Respiration Is Impaired during Late-Stage Hamster Prion Infection. Journal of Virology, 2017, 91, .	3.4	26
36	Proteomics Analysis of Amyloid and Nonamyloid Prion Disease Phenotypes Reveals Both Common and Divergent Mechanisms of Neuropathogenesis. Journal of Proteome Research, 2014, 13, 4620-4634.	3.7	20

#	Article	IF	Citations
37	PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection. Journal of Virology, 2017, 91, .	3.4	19
38	Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies. Current Opinion in Microbiology, 1999, 2, 563-566.	5.1	17
39	The Distribution of Prion Protein Allotypes Differs Between Sporadic and Iatrogenic Creutzfeldt-Jakob Disease Patients. PLoS Pathogens, 2016, 12, e1005416.	4.7	15
40	Cell biology of prion infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 45-68.	1.8	14
41	Molecular aspects of disease pathogenesis in the transmissible spongiform encephalopathies. Molecular Biotechnology, 2006, 33, 71-88.	2.4	14
42	Molecular Aspects of Disease Pathogenesis in the Transmissible Spongiform Encephalopathies. , 2004, 268, 517-540.		13
43	A Specific Population of Abnormal Prion Protein Aggregates Is Preferentially Taken Up by Cells and Disaggregated in a Strain-Dependent Manner. Journal of Virology, 2013, 87, 11552-11561.	3.4	12
44	Identification of possible animal origins of prion disease in human beings. Lancet, The, 2004, 363, 2013-2014.	13.7	10
45	Proteomics applications in prion biology and structure. Expert Review of Proteomics, 2015, 12, 171-184.	3.0	8
46	Lack of Prion Infectivity in Fixed Heart Tissue from Patients with Creutzfeldt-Jakob Disease or Amyloid Heart Disease. Journal of Virology, 2013, 87, 9501-9510.	3.4	6
47	Cell Biology Approaches to Studying Prion Diseases. Methods in Molecular Biology, 2017, 1658, 83-94.	0.9	5
48	Transmission characteristics of heterozygous cases of Creutzfeldt-Jakob disease with variable abnormal prion protein allotypes. Acta Neuropathologica Communications, 2020, 8, 83.	5.2	5
49	Cell biology of prion strains in vivo and in vitro. Cell and Tissue Research, 2022, , .	2.9	5
50	Processing of high-titer prions for mass spectrometry inactivates prion infectivity. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2018, 1866, 1174-1180.	2.3	4
51	Methods for Studying Prion Protein (PrP) Metabolism and the Formation of Protease-Resistant PrP in Cell Culture and Cell-Free Systems. , 1996, , 285-300.		3
52	Relative Abundance of apoE and AÎ²1â€“42 Associated with Abnormal Prion Protein Differs between Creutzfeldt-Jakob Disease Subtypes. Journal of Proteome Research, 2016, 15, 4518-4531.	3.7	3
53	The Size and Stability of Infectious Prion Aggregates Fluctuate Dynamically during Cellular Uptake and Disaggregation. Biochemistry, 2021, 60, 398-411.	2.5	3
54	Species Barriers in Prion Disease. , 2013, , 139-154.		3

#	Article	IF	Citations
55	Lack of the immune adaptor molecule SARM1 accelerates disease in prion infected mice and is associated with increased mitochondrial respiration and decreased expression of NRF2. PLoS ONE, 2022, 17, e0267720.	2.5	2
56	Altered distribution, aggregation, and protease resistance of cellular prion protein following intracranial inoculation. PLoS ONE, 2019, 14, e0219457.	2.5	1
57	Therapeutic Potential of Prion Protein Peptides in the Transmissible Spongiform Encephalopathies. Laboratory Medicine, 2002, 33, 369-373.	1.2	0